Plain-English translation of NCT06735027 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different injection approaches to treat shoulder pain caused by arthritis or rotator cuff damage. One approach uses methylprednisolone acetate, a corticosteroid injected directly into the shoulder joint. The other uses a nerve block with numbing medication and a steroid injected near a nerve that controls shoulder pain. The study wants to see which approach works better for people who want to avoid surgery.
Shoulder arthritis and rotator cuff damage can cause chronic pain, and many patients prefer to try non-surgical treatments first. While steroid injections into the joint are commonly used, nerve blocks are a less common option that might offer pain relief with different benefits—and researchers want to compare how well these two approaches actually work.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive one of the two injection treatments. One group receives an injection directly into the shoulder joint, while the other receives an injection near a nerve in the shoulder area. The study will likely involve an initial visit for the injection procedure, with follow-up visits to track how much your pain improves over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Sponsor
University of Minnesota
Enrollment target
~40 participants
Started
January 2025
Primary completion
January 2027
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Allison Rao
University of Minnesota
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.